Blood and cell products and services company OrganaBio LLC and RxMP Therapeutics Inc, a late pre-clinical development stage therapeutics company developing novel therapies for the rapid control of severe haemorrhage, on Wednesday announced a manufacturing partnership under which OrganaBio will serve as RxMP's contract manufacturing partner for the cGMP production of its lead product candidate, RMP-402.

OrganaBio will support the technology transfer, qualification, and cGMP production of RMP-402, leveraging its integrated manufacturing infrastructure and quality management systems to advance the drug product through key development milestones. The collaboration brings together OrganaBio's capabilities in cGMP manufacturing, quality assurance, and analytical development with RxMP's proprietary haemostatic platform technology.

RMP-402 is a first-in-class haemostatic therapeutic composed of manufactured allogeneic red cell membrane particles (RMPs) -- analogues of particles that circulate naturally in human blood. These RMPs are designed to rapidly stop bleeding when administered intravenously without increasing the risk of off-target clotting.

RMP-402 is being developed for use in both civilian and military settings, addressing a global trauma and surgical bleeding market estimated at USD12bn annually, where uncontrolled bleeding remains a leading cause of morbidity and preventable death. In 2025, RxMP reached consensus with the US Food and Drug Administration (FDA) on its proposed GMP manufacturing process for RMP-402 and entered into a Cooperative Research and Development Agreement (CRADA) with the US Department of Defense's Institute of Surgical Research to further validate the product's therapeutic potential for the treatment of combat casualties.